{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T10:58:18Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 21.8, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09543-7307-7972-9957-5d4da42964c8\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: ligustrazine\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 re", "usd": 0.0, "recall": true }, "codex": { "seconds": 78.1, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09543-730d-72c2-943f-a4c4609720ef\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: ligustrazine\nRegistry id: vr.tr.ligustrazine\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:50:01+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:25+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q11319317", "registryId": "vr.tr.ligustrazine", "name": "ligustrazine", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q11319317/", "model": { "registry_id": "vr.tr.ligustrazine", "name": "ligustrazine", "purpose": "Enable an agent to identify ligustrazine, assess the form and quality of a material containing it, and determine which handling or use decisions the available evidence supports.", "definition": "Ligustrazine, or 2,3,5,6-tetramethylpyrazine, is an aromatic nitrogen heterocycle with molecular formula C8H12N2, associated with the medicinal plant Ligusticum chuanxiong and also encountered as an aroma compound.", "scope_statement": "This model owns the chemical identity and material-state assessment of ligustrazine under vr.tr.ligustrazine in PHY / PHY.MAT, with explicit boundaries between the parent compound, its salts, source extracts and formulated products.", "in_scope": [ "Parent-compound identity, synonyms and authoritative chemical identifiers", "Relationships to salt forms, hydrates and dissolved species", "Batch composition, assay basis, impurities and grade", "Physical properties, solubility and stability under recorded conditions", "Evidence supporting biological activity, handling requirements and use eligibility" ], "out_of_scope": [ "Botanical identity, cultivation and whole-extract composition of source plants", "Complete manufacturing or extraction process models", "Finished medicine formulations, packaging and administration devices", "Patient-specific treatment, dosing and clinical decisions", "Food formulations and sensory properties of complete foods" ], "distinguishing_features": [ "Ligustrazine denotes 2,3,5,6-tetramethylpyrazine: a pyrazine ring with methyl substituents at all four carbon positions; matching only the abbreviation TMP is insufficient. [PubChem identity record](https://pubchem.ncbi.nlm.nih.gov/compound/tetramethylpyrazine)", "The parent compound has molecular formula C8H12N2, molecular weight 136.19 g/mol, CAS 1124-11-4 and PubChem CID 14296; a candidate record should agree across structure and identifiers. [PubChem identity record](https://pubchem.ncbi.nlm.nih.gov/compound/tetramethylpyrazine)", "Ligustrazine hydrochloride requires a counterion-aware identity and must not inherit the parent's formula or mass basis unchanged. [PubChem hydrochloride record](https://pubchem.ncbi.nlm.nih.gov/compound/156709)", "A plant extract, food or formulation containing ligustrazine is not equivalent to an isolated ligustrazine batch; recognition requires composition and analytical evidence." ], "characteristics": [ { "name": "Chemical identity", "kind": "category", "unit_or_values": "Structure-resolved name, CAS, PubChem CID, verified EC number and identifier source", "why_it_matters": "Prevents synonym collisions and accidental assignment of salt or product identifiers to the parent." }, { "name": "Material form", "kind": "category", "unit_or_values": "Free base, specified salt, hydrate or solvate, solution, mixture, unresolved", "why_it_matters": "Determines which formula, molecular mass and property evidence applies." }, { "name": "Ligustrazine content", "kind": "measurement", "unit_or_values": "% mass fraction, mg/g or mol/L; state as-is, dry, salt or free-base-equivalent basis", "why_it_matters": "Makes quantities comparable without mistaking salt mass or chromatographic area for parent-compound content." }, { "name": "Impurity profile", "kind": "measurement", "unit_or_values": "Individual impurities, residual solvents and water in mg/kg or % mass fraction, with method and detection limits", "why_it_matters": "Supports acceptance for a defined use and investigation of contamination or degradation." }, { "name": "Phase and thermal behavior", "kind": "measurement", "unit_or_values": "Observed phase; melting range and boiling or decomposition behavior in °C with pressure, form and method", "why_it_matters": "Supports identity checks, storage assessment and processing decisions." }, { "name": "Solubility and solution conditions", "kind": "measurement", "unit_or_values": "g/L or mol/L with solvent, temperature, pH and material form", "why_it_matters": "Determines whether a preparation can achieve and maintain its intended concentration." }, { "name": "Batch provenance and grade", "kind": "relation", "unit_or_values": "Supplier, lot, production-route record, certificate of analysis and documented grade specification", "why_it_matters": "Links a material decision to traceable evidence instead of a name or marketing label." }, { "name": "Storage fitness", "kind": "state", "unit_or_values": "Within supported conditions, excursion pending assessment, retest required, rejected, unknown", "why_it_matters": "Separates current material fitness from an unchanged chemical label." }, { "name": "Biological evidence context", "kind": "relation", "unit_or_values": "Study, tested form, concentration or exposure, experimental system, endpoint and evidence level", "why_it_matters": "Prevents activity findings from becoming unsupported therapeutic claims." }, { "name": "Safety and use status", "kind": "relation", "unit_or_values": "Applicable SDS, GHS classification, exposure-limit source and jurisdiction-specific use record with date", "why_it_matters": "Keeps handling and eligibility decisions specific to the material and intended activity." } ], "affordances": [ "Resolve a ligustrazine label against structure and identifiers, flagging ambiguous abbreviations or salt records.", "Compare a batch's identity, assay and impurity results with the specification for its intended use.", "Convert a specified salt quantity to free-base equivalents when stoichiometry, hydration and assay basis are known.", "Assess whether a proposed solvent and concentration have supporting solubility and stability evidence.", "Determine whether storage excursions require retesting, quarantine or rejection.", "Retrieve evidence relevant to an intended research or commercial use while retaining its material-form and jurisdiction limits." ], "agent_conduct": { "may": [ "Identify ligustrazine from analytical data and report the grade and source of a sample.", "Describe its documented uses as a flavour compound and in traditional medicine, citing sources." ], "must_not": [ "Recommend ligustrazine or herbal products containing it as a treatment for a person's condition.", "Present traditional medicine claims about it as established clinical evidence.", "Label an unanalysed plant extract as pure ligustrazine.", "Help supply it as a medicine where it is not authorized for that use." ], "requires_human": [ "Using ligustrazine in a food, supplement or medicine intended for people.", "Disposing of bulk quantities in a laboratory." ] }, "ethics": { "considerations": [ "Traditional medicine claims can mislead patients into delaying effective treatment.", "Respect for the medical traditions that use it should not replace evidence about safety." ], "affected_parties": [ "Patients and consumers", "Laboratory workers", "Practitioners of traditional medicine" ] }, "owners": { "steward": "The laboratory or business that holds the material; medicines regulators decide on any therapeutic use.", "master_systems": [] }, "visual_identification": [ "A white crystalline solid with a nutty or roasted odour, which does not settle identity on its own.", "Identity is settled by spectroscopy, chromatography or melting point against a reference." ], "failure_modes_and_hazards": [ "Unsupervised medicinal use can interact with blood-thinning or other medicines.", "Misidentified or contaminated extracts can expose consumers to unknown substances." ], "standards_and_regulation": [ "Globally Harmonized System of Classification and Labelling of Chemicals (GHS), United Nations." ], "what_it_is_for": [ "Ligustrazine is encountered in chemical research, medicinal plant analysis and studies of aroma compounds in foods.", "Analytical laboratories use it as a target compound or reference material when investigating composition and identity.", "Pharmacological research examines its biological activity, with interpretation depending on the chemical form, purity and study context." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q11319317: ligustrazine", "url": "https://www.wikidata.org/wiki/Q11319317", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Tetramethylpyrazine", "url": "https://en.wikipedia.org/wiki/Tetramethylpyrazine", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "ligustrazine-identity-and-forms", "name": "Ligustrazine identity and forms", "description": "Establish which records and materials denote the parent compound and which denote related forms.", "rationale": "Ligustrazine names can travel across free-base, salt and product records whose quantities and properties are not interchangeable.", "layers": [ { "id": "parent-structure-and-identifiers", "name": "Parent structure and identifiers", "description": "Resolve the registry entry to a chemically explicit identity.", "findings": [ { "id": "identity-concordance", "name": "Identity concordance", "description": "Require agreement between the ligustrazine name, tetramethylpyrazine structure and external identifiers.", "questions": [ { "text": "Does the candidate material match 2,3,5,6-tetramethylpyrazine rather than a different compound abbreviated TMP?", "kind": "definition", "id": "identity-concordance-q01" }, { "text": "Which authoritative records establish its CAS, PubChem CID and EC number, and do their structures agree?", "kind": "provenance", "id": "identity-concordance-q02" } ] } ] }, { "id": "salt-and-mixture-boundaries", "name": "Salt and mixture boundaries", "description": "Distinguish the parent moiety from counterion-bearing materials and mixtures.", "findings": [ { "id": "form-resolved-material", "name": "Form-resolved material", "description": "Record form relationships without creating an unsupported registry split.", "questions": [ { "text": "Is the material the free base, a specified hydrochloride or phosphate salt, another form, or a mixture?", "kind": "boundary", "id": "form-resolved-material-q01" }, { "text": "What counterion stoichiometry, hydration or solvation evidence determines its formula and mass basis?", "kind": "measurement", "id": "form-resolved-material-q02" }, { "text": "Does a linked registry model already own this form or containing product?", "kind": "boundary", "id": "form-resolved-material-q03" } ] } ] } ] }, { "id": "ligustrazine-batch-quality", "name": "Ligustrazine batch quality", "description": "Establish what a particular batch contains and how confidently that composition is known.", "rationale": "A ligustrazine label or purity percentage alone cannot establish usable parent-compound content or suitability.", "layers": [ { "id": "identity-and-assay", "name": "Identity and assay", "description": "Tie identity confirmation and quantitative content to suitable analytical evidence.", "findings": [ { "id": "analytical-confirmation", "name": "Analytical confirmation", "description": "Assess whether identity and content are demonstrated rather than inferred from a supplier label.", "questions": [ { "text": "Which reference standard and analytical results confirm ligustrazine identity in this matrix?", "kind": "provenance", "id": "analytical-confirmation-q01" }, { "text": "Does the reported assay measure mass content, chromatographic area, salt content or free-base equivalents?", "kind": "measurement", "id": "analytical-confirmation-q02" }, { "text": "What uncertainty and method limitations affect acceptance of the reported content?", "kind": "measurement", "id": "analytical-confirmation-q03" } ] } ] }, { "id": "impurities-and-grade", "name": "Impurities and grade", "description": "Connect route-specific contaminants and batch documentation to intended use.", "findings": [ { "id": "grade-supported-acceptance", "name": "Grade-supported acceptance", "description": "Judge a batch against an explicit specification rather than treating all ligustrazine grades as equivalent.", "questions": [ { "text": "Which related pyrazines, residual solvents, water and other route-relevant impurities were measured?", "kind": "measurement", "id": "grade-supported-acceptance-q01" }, { "text": "What lot-specific records support the claimed synthetic, extracted or fermentation-derived provenance?", "kind": "provenance", "id": "grade-supported-acceptance-q02" }, { "text": "Which documented acceptance limits make this batch suitable for the proposed analytical, research, food or pharmaceutical use?", "kind": "action", "id": "grade-supported-acceptance-q03" } ] } ] } ] }, { "id": "ligustrazine-physical-state-and-preparation", "name": "Ligustrazine physical state and preparation", "description": "Describe the form-dependent properties needed to inspect and prepare ligustrazine materials.", "rationale": "Thermal constants and solution behavior require a known form and conditions before they can guide action.", "layers": [ { "id": "solid-and-thermal-properties", "name": "Solid and thermal properties", "description": "Evaluate phase observations and thermal measurements for the identified material.", "findings": [ { "id": "conditioned-physical-constants", "name": "Conditioned physical constants", "description": "Attach each physical constant to its tested form, purity and measurement conditions.", "questions": [ { "text": "What phase and melting range are supported for the identified ligustrazine form at the recorded purity?", "kind": "measurement", "id": "conditioned-physical-constants-q01" }, { "text": "Which boiling-point or decomposition measurements are available, and at what pressure and method conditions?", "kind": "measurement", "id": "conditioned-physical-constants-q02" } ] } ] }, { "id": "dissolution-and-equivalent-content", "name": "Dissolution and equivalent content", "description": "Support solution preparation without transferring properties or mass conversions across unspecified forms.", "findings": [ { "id": "supported-solution-preparation", "name": "Supported solution preparation", "description": "Determine whether an intended ligustrazine concentration can be prepared and meaningfully reported.", "questions": [ { "text": "What measured solubility supports the target concentration in the chosen solvent at the intended pH and temperature?", "kind": "measurement", "id": "supported-solution-preparation-q01" }, { "text": "What stoichiometry, water content and assay corrections are needed to express this preparation as ligustrazine free-base equivalents?", "kind": "measurement", "id": "supported-solution-preparation-q02" }, { "text": "What evidence indicates precipitation or concentration change after dilution or a change in pH?", "kind": "action", "id": "supported-solution-preparation-q03" } ] } ] } ] }, { "id": "ligustrazine-stability-and-handling", "name": "Ligustrazine stability and handling", "description": "Connect storage history and safety evidence to the current material.", "rationale": "Neither parent-compound identity nor an initial assay establishes continued fitness or appropriate handling.", "layers": [ { "id": "storage-and-retest", "name": "Storage and retest", "description": "Assess stability separately for the supplied solid and prepared solutions.", "findings": [ { "id": "retained-material-fitness", "name": "Retained material fitness", "description": "Determine whether storage evidence supports continued use of the ligustrazine batch or preparation.", "questions": [ { "text": "Which stability studies support temperature, light, moisture and container conditions for this exact form?", "kind": "provenance", "id": "retained-material-fitness-q01" }, { "text": "What assay, impurity or appearance changes define failure after storage or solution preparation?", "kind": "measurement", "id": "retained-material-fitness-q02" }, { "text": "What retest or quarantine decision follows the recorded excursion and elapsed storage time?", "kind": "action", "id": "retained-material-fitness-q03" } ] } ] }, { "id": "form-specific-hazards", "name": "Form-specific hazards", "description": "Resolve handling requirements against the actual substance or mixture being used.", "findings": [ { "id": "applicable-safety-evidence", "name": "Applicable safety evidence", "description": "Keep ligustrazine hazard evidence distinct from hazards contributed by solvents, counterions or formulation ingredients.", "questions": [ { "text": "Which current SDS and GHS classification apply to the identified form, concentration and jurisdiction?", "kind": "provenance", "id": "applicable-safety-evidence-q01" }, { "text": "Is a substance-specific occupational exposure limit established, or is that information absent?", "kind": "definition", "id": "applicable-safety-evidence-q02" }, { "text": "What handling, spill and disposal measures follow from the applicable evidence for the planned operation?", "kind": "action", "id": "applicable-safety-evidence-q03" } ] } ] } ] }, { "id": "ligustrazine-activity-and-use-evidence", "name": "Ligustrazine activity and use evidence", "description": "Bound biological and use claims by their evidence, tested material and governing context.", "rationale": "The same chemical name can appear in experimental, medicinal and flavouring contexts with different evidentiary requirements.", "layers": [ { "id": "biological-claim-boundaries", "name": "Biological claim boundaries", "description": "Represent activity claims without equating experimental effects with established clinical benefit.", "findings": [ { "id": "exposure-linked-activity", "name": "Exposure-linked activity", "description": "Associate each proposed effect with the tested ligustrazine form, exposure and study design.", "questions": [ { "text": "For a claimed platelet, vascular or neuroprotective effect, what primary study identifies the tested form and measured endpoint?", "kind": "provenance", "id": "exposure-linked-activity-q01" }, { "text": "What concentration or exposure produced the result, and how were vehicle effects, impurities and toxicity assessed?", "kind": "measurement", "id": "exposure-linked-activity-q02" }, { "text": "Does the evidence concern a biochemical assay, cells, animals or humans, and what inference remains unsupported?", "kind": "boundary", "id": "exposure-linked-activity-q03" } ] } ] }, { "id": "use-and-jurisdiction", "name": "Use and jurisdiction", "description": "Link a proposed use to applicable records without interpreting chemical registration as blanket authorization.", "findings": [ { "id": "use-specific-eligibility", "name": "Use-specific eligibility", "description": "Determine which authority and specification govern the proposed ligustrazine use.", "questions": [ { "text": "What current official record governs this form's intended medicinal, flavouring or research use in the relevant jurisdiction?", "kind": "provenance", "id": "use-specific-eligibility-q01" }, { "text": "Does that record apply to the parent substance, a particular salt, a grade or a finished product?", "kind": "boundary", "id": "use-specific-eligibility-q02" }, { "text": "What additional material documentation is required before the proposed use can proceed?", "kind": "action", "id": "use-specific-eligibility-q03" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recalled information; no sources were consulted.", "Verify salt stoichiometry, hydration state, purity, physical constants and current hazard classification for the specific material.", "Experimental pharmacological findings do not by themselves establish clinical efficacy; verify current approvals and supporting clinical evidence." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of ligustrazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Ligustrazine free base", "Ligustrazine hydrochloride", "Ligustrazine phosphate" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of ligustrazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "CAS Registry Number", "value_or_pattern": "1124-11-4", "note": "Identifies tetramethylpyrazine free base; salts require separate identifiers." }, { "scheme": "Systematic chemical name", "value_or_pattern": "2,3,5,6-tetramethylpyrazine", "note": "Specifies methyl substitution at all four carbon positions of the pyrazine ring." }, { "scheme": "Molecular formula", "value_or_pattern": "C8H12N2", "note": "Free-base composition; a molecular formula alone does not uniquely identify a substance." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of ligustrazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Used as an aroma or flavour ingredient associated with roasted and nutty notes.", "Ligustrazine salts are used in pharmaceutical preparations in China.", "Studied experimentally for vascular, platelet-related and neuroprotective effects." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of ligustrazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass of the free base", "typical_range": "136.20", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of ligustrazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Confusing the free base with a salt or hydrate can produce incorrect mass-based concentration calculations.", "Substituting flavouring or research material for pharmaceutical-grade material can introduce unsuitable impurities or quality characteristics." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of ligustrazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Pharmaceutical use is particularly associated with China; authorization and permitted indications must be established separately for each jurisdiction." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of ligustrazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Pyrazine", "difference": "Pyrazine is the unsubstituted parent ring; ligustrazine has four methyl substituents." }, { "name": "Ligusticum chuanxiong", "difference": "The plant is a biological source containing many constituents; ligustrazine is one defined chemical compound." }, { "name": "Ligustilide", "difference": "Ligustilide is a chemically distinct phthalide constituent associated with related medicinal plants, rather than a methylated pyrazine." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of ligustrazine this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which existing Vercy models, if any, already own tetramethylpyrazine or its salt forms, and how should this entry link to them without duplicating ownership?", "What verified EC identifier, jurisdiction-specific GHS classifications and occupational exposure limits apply to the parent compound and relevant supplied forms?", "Which primary measurements establish form-specific melting, boiling or decomposition behavior, aqueous solubility and pH dependence?", "Which validated specifications distinguish acceptable ligustrazine grades, including route-dependent impurities and free-base-equivalent assay conventions?", "Which current official use records and primary human studies support medicinal or flavouring claims, and which claims remain experimental?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 18, "questions": 36 } }